Pfizer has appointed Tanya Alcorn as President, Global Hospital and Biosimilars, expanding her leadership responsibilities after serving more than three years as Senior Vice President of Operations.
In her new role, Alcorn will lead Pfizer’s global hospital-focused portfolio, including sterile injectables and biosimilars, overseeing an integrated model that brings together commercial strategy, manufacturing, and supply chain operations. The move is part of Pfizer’s efforts to streamline decision-making and strengthen delivery of essential medicines worldwide.
Alcorn has spent over 26 years at Pfizer, joining the company in 1999 as a Quality Assurance Specialist. Over the course of her career, she has held senior leadership roles across technology, biotechnology strategy, and global supply chain operations. Most recently, she was responsible for overseeing end-to-end operations supporting Pfizer’s biopharmaceutical manufacturing network.
Between 2018 and 2022, Alcorn served as Vice President of BioPharma Global Supply Chain, managing demand, supply, and inventory across hundreds of products and international markets. Her experience spans both internal manufacturing and external production partnerships.
Pfizer’s hospital and biosimilars portfolio plays a key role in expanding access to critical medicines, including biologics and biosimilars designed to provide comparable clinical outcomes to reference biologic therapies. Biosimilars are developed to closely match the structure and function of complex biologic medicines, helping reduce costs and improve patient access globally.
Under the new organizational structure, Pfizer aims to apply a coordinated “plant-to-patient” approach to manage and prioritize hospital medicines more efficiently, while maintaining high standards for quality, safety, and supply reliability.
The appointment underscores Pfizer’s continued focus on strengthening leadership across essential medicines and biosimilars as demand grows across global healthcare systems.
By
